Reset
Showing 20 of 65 academic articles

Health-related quality of life in Chinese population with non-alcoholic fatty liver disease: a national multicenter survey

Rui Huang, Jian-Gao Fan, Jun-Ping Shi, Yi-Min Mao et al. • Health and Quality of Life Outcomes (2021)

Abstract Background Health Related Quality of Life (HRQL) is a multi-dimensional construct that can comprehensively evaluate the patient’s health status, including physical, emotional, mental and social well-being. In this study, we aimed t...

DOAJ Open Access (DOAJ) DOI: 10.1186/s12955-021-01778-w

Electronic symptom monitoring of patient-reported outcomes among patients with hepatocellular carcinoma during immunotherapy (PRIME-HCC): protocol for a randomised controlled trial

Yanshang Wang, Xiaoping Wei • BMJ Open (2026)

Introduction Electronic patient-reported outcome (ePROs)-based symptom monitoring benefits health-related quality of life (HRQoL) in various cancers. However, despite the high disease and economic burden of hepatocellular carcinoma (HCC) an...

DOAJ Open Access (DOAJ) DOI: 10.1136/bmjopen-2026-116199

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumors

Dan Lu, Yuan Chen, Min Jiang, Jie Wang et al. • Nature Communications (2023)

Abstract KRAS mutations are broadly recognized as promising targets for tumor therapy. T cell receptors (TCRs) can specifically recognize KRAS mutant neoantigens presented by human lymphocyte antigen (HLA) and mediate T cell responses to el...

DOAJ Open Access (DOAJ) DOI: 10.1038/s41467-023-42010-1

Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy

Wei Liu, Yan Xu, Yi Wang, Lugui Qiu et al. • Journal for ImmunoTherapy of Cancer (2024)

Background Over 50% of patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) receiving CD19-targeted chimeric antigen receptor (CAR19) T-cell therapy fail to achieve durable remission. Early identification of relapse or prog...

DOAJ Open Access (DOAJ) DOI: 10.1136/jitc-2023-008450

Unveiling the immunomodulatory dance: endothelial cells’ function and their role in non-small cell lung cancer

Sophia Daum, Lilith Decristoforo, Mira Mousa, Stefan Salcher et al. • Molecular Cancer (2025)

Abstract The dynamic interactions between tumor endothelial cells (TECs) and the immune microenvironment play a critical role in the progression of non-small cell lung cancer (NSCLC). In general, endothelial cells exhibit diverse immunomodu...

DOAJ Open Access (DOAJ) DOI: 10.1186/s12943-024-02221-6

Molecular characterization and prognostic modeling associated with M2-like tumor-associated macrophages in breast cancer: revealing the immunosuppressive role of DLG3

Ziqiang Wang, Jing Zhang, Huili Chen, Xinyu Zhang et al. • Frontiers in Immunology (2025)

BackgroundM2-like tumor-associated macrophages (TAMs) promote an immunosuppressive microenvironment and contribute to tumor progression and metastasis. However, their molecular characterization and prognostic value have not been fully explo...

DOAJ Open Access (DOAJ) DOI: 10.3389/fimmu.2025.1650726

Case Report: Tocilizumab in pediatric febrile infection-related epilepsy syndrome

Lingyu Pang, Lingyu Pang, Lingyu Pang, Xuefang Liu et al. • Frontiers in Immunology (2026)

Background and purposeWe describe the clinical characteristics and the therapeutic effect of tocilizumab with Febrile Infection-Related Epilepsy Syndrome (FIRES). FIRES is characterized by super refractory status epilepticus (SRSE) in previ...

DOAJ Open Access (DOAJ) DOI: 10.3389/fimmu.2026.1767388

Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors

Safwaan H. Khan, Safwaan H. Khan, Yeonjoo Choi, Mysore Veena et al. • Frontiers in Immunology (2025)

Chimeric antigen receptor (CAR) T cell therapy has revolutionized the treatment of hematologic malignancies, achieving remarkable clinical success with FDA-approved therapies targeting CD19 and BCMA. However, the extension of these successe...

DOAJ Open Access (DOAJ) DOI: 10.3389/fimmu.2024.1489827

Basic and Clinical Immunology.

• Annals of Internal Medicine (1979)

This text and review has been updated and revised since the last edition in 1974. The normal immunologic function and disease processes are presented clearly. New features include emphasis on normal immunologic function and disease processe...

OPENALEX DOI: https://doi.org/10.7326/0003-4819-90-4-732_3

Case Report: A severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib

Mark W. D. Sweep, Mark W. D. Sweep, Martijn J. H. Tjan, Mark A. J. Gorris et al. • Frontiers in Immunology (2023)

Immune checkpoint inhibitor therapy for cancer treatment can give rise to a variety of adverse events. Here we report a male patient with metastatic melanoma who experienced life-threatening colitis and duodenitis following treatment with i...

DOAJ Open Access (DOAJ) DOI: 10.3389/fimmu.2023.1212432

Topical Pharmacological Treatment of Actinic Keratoses: Focus on Tirbanibulin 1% Ointment

Mario Valenti, Matteo Bianco, Alessandra Narcisi, Antonio Costanzo et al. • Dermatology Practical & Conceptual (2024)

Actinic keratosis (AK) is a frequent precancerous skin lesion that mostly affects chronically sun-exposed areas. Chronic sun damage leads to various mutations in onco-suppressor and oncogenic genes which cause an uncontrolled proliferation ...

DOAJ Open Access (DOAJ) DOI: 10.5826/dpc.1403S1a145S

Immunogenic cell death-related macrophage gene model for prognostic prediction in glioblastoma

Yiming Mao, Ting Li, Wenqiang Lu, Chunhong Li et al. • Discover Oncology (2025)

Abstract Glioblastoma (GBM) is an extremely aggressive and diverse type of brain tumor that is associated with a poor prognosis. Immunogenic cell death (ICD) is a particular form of cellular demise that is closely linked to antineoplastic i...

DOAJ Open Access (DOAJ) DOI: 10.1007/s12672-025-03557-1